A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).

Exclusion Criteria

• •Clinical, laboratory, imaging, or histopathologic evidence of other causes of acute or chronic liver disease, including autoimmune, viral, metabolic, or alcoholic liver disease.
• •Clinical evidence of compensated or decompensated hepatic cirrhosis as assessed by historical liver histology, ultrasound-based and/or signs and symptoms of hepatic decompensation (including, but not limited to, jaundice, ascites, variceal hemorrhage, and/or hepatic encephalopathy).
• •Presence of hepatic impairment, end-stage liver disease, and/or a model for end-stage liver disease (MELD) score \>12.
• •Transient elastography read \>20.0 kPA within 3 months prior to or during the Screening Period.
• •Estimated glomerular filtration rate \<45 mL/min based on the 2021 CKD-EPI creatinine equation.
• •Poor nutritional status defined as body mass index (BMI) \<17 kg/m2.